<html>
<head>
<title></title>
<!--Licensed to: Emergent
    Document created using Disclosure Solutions PROFILE 1.3.2.0
    Copyright 1995 - 2014 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 11pt">&#160;<font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 11pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">____________________</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 8-K</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act of 1934</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">Date of report (Date of earliest event reported): <font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 21, 2014</font></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 14pt; FONT-WEIGHT: bold">Emergent BioSolutions Inc.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">(Exact Name of Registrant as Specified in Charter)</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</div>
</td>
<td style="WIDTH: 30%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">001-33137</div>
</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">14-1902018</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">(State or Other Jurisdiction</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">of Incorporation)</div>
</td>
<td style="WIDTH: 30%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">(Commission</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">File Number)</div>
</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">(IRS Employer</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Identification No.)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 65%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2273 Research Boulevard, Suite 400, Rockville, Maryland</div>
</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">20850</div>
</td>
</tr>

<tr>
<td style="WIDTH: 65%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">(Address of Principal Executive Offices)</div>
</td>
<td style="WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">(Zip Code)</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">Registrant's telephone number, including area code: <font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(301) 795-1800</font></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Not applicable</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">(Former Name or Former Address, if Changed Since Last Report)</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">&#160;<font style="FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">&#160;<font style="FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">&#160;<font style="FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt">&#160;<font style="FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 10pt; FONT-SIZE: 11pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<hr style="HEIGHT: 2px; COLOR: #000000">
</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item&#160;2.01</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Completion of Acquisition or Disposition of Assets.</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">On February 21, 2014, Emergent BioSolutions Inc. and its wholly-owned subsidiary, 2396638 Ontario Inc. ("Acquisition Sub"), completed the previously announced acquisition of Cangene Corporation, an Ontario corporation, in accordance with the Arrangement Agreement, dated as of December 11, 2013 (the "Arrangement Agreement"), among Emergent, Acquisition Sub and Cangene. Acquisition Sub paid $222 million in cash, or $3.24 per share (on a fully diluted basis), to acquire all of the outstanding common shares of Cangene. The acquisition was funded, in part, by proceeds from an offering by Emergent of its 2.875% Convertible Senior Notes due 2021 (the "Notes"), which closed on January 29, 2014.</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Cangene is a Canadian biopharmaceutical company focused on the development and commercialization of specialty therapeutics, primarily targeting biodefense applications as well as infectious disease, hematology and transplantation.</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Additional information and details of the Arrangement Agreement and the Notes, respectively, were previously disclosed in Item&#160;1.01 of Emergent's Form 8-K filed on December 11, 2013 and Item&#160;1.01 of Emergent's Form 8-K filed on January 29, 2014, both of which are incorporated by reference into this Item&#160;2.01.</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">&#160;The foregoing is a summary description of certain terms of the Arrangement Agreement and does not purport to be complete. It is qualified in its entirety by reference to the full text of the Arrangement Agreement, which was attached as Exhibit 2 to Emergent's Form 8-K filed on December 11, 2013.</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">The representations and warranties of Emergent, Cangene and Acquisition Sub contained in the Arrangement Agreement were made solely for the benefit of the parties to the Arrangement Agreement. In addition, such representations and warranties (1) were made only for purposes of the Arrangement Agreement, (2) may be subject to limits or exceptions agreed upon by the contracting parties, (3) are subject to materiality qualifications contained in the Arrangement Agreement which may differ from what may be viewed as material by investors, (4) were made only as of the date of the Arrangement Agreement or other specific dates and (5) have been included in the Arrangement Agreement for the purpose of allocating risk between the contracting parties rather than establishing matters as facts. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Emergent, Cangene or any of their respective subsidiaries or affiliates. Additionally, the representations, warranties, covenants, conditions and other terms of the Arrangement Agreement were made subject to subsequent waiver or modification. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Arrangement Agreement, which subsequent information may or may not be fully reflected in Emergent's or Cangene's public disclosures.</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item&#160;7.01</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Regulation FD Disclosure.</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 4.5pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">A copy of the Company's press release, dated February 21, 2014, announcing completion of the acquisition is attached to this report on Form 8-K as Exhibit 99 and is incorporated herein by reference.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 13.5pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item&#160;9.01</div>
</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Statements and Exhibits.</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 4.5pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">(a) Financial Statements of Business Acquired</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">The audited consolidated financial statements of Cangene Corporation, including the consolidated balance sheets as at July 31, 2013 and 2012 and the consolidated statements of income (loss) and comprehensive income (loss), changes in equity and cash flows for the years ended July 31, 2013 and 2012, were included as Exhibit 99.1 to Emergent's Form 8-K filed on January 22, 2014, which is incorporated herein by reference.</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">The audited consolidated financial statements of Cangene Corporation, including the consolidated balance sheets as at July 31, 2012 and 2011 and the consolidated statements of income (loss) and comprehensive income (loss), changes in equity and cash flows for the years ended July 31, 2012 and 2011, were included as Exhibit 99.2 to Emergent's Form 8-K filed on January 22, 2014, which is incorporated herein by reference.</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">The unaudited condensed consolidated interim financial statements of Cangene Corporation, including the condensed consolidated interim balance sheets as at October 31, 2013 and July 31, 2013 and the condensed consolidated interim statements of income (loss) and comprehensive income (loss), changes in equity and cash flows for the three months ended October 31, 2013 and 2012, were included as Exhibit 99.3 to Emergent's Form 8-K filed on January 22, 2014, which is incorporated herein by reference.</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">(b) Pro Forma Financial Information</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">The unaudited pro forma combined financial statements reflecting the acquisition were included as Exhibit 99.4 to Emergent's Form 8-K filed on January 22, 2014, which is incorporated herein by reference. The unaudited pro forma combined financial statements were prepared prior to the issuance of the Notes. The actual aggregate principal amount of Notes issued in the offering was $250 million, representing $50 million more than the aggregate principal amount of Notes assumed in the pro forma combined financial statements, which results in a $1.4 million increase in pro forma interest expense for the year ended December&#160;31, 2012, a $1.1 million increase in pro forma interest expense for the nine months ended September, 2013, a $0.03 decrease in basic earnings per share for the year ended December 31, 2012, and a $0.02 decrease in basic earnings per share for the nine months ended September 30, 2013.</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 9pt; TEXT-INDENT: 24.5pt; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">(d) Exhibits</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 9pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: middle" colspan="3">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.22%; VERTICAL-ALIGN: middle">
<div>&#160;</div>
</td>
<td style="WIDTH: 0.9%; VERTICAL-ALIGN: middle">
<div>&#160;</div>
</td>
<td style="WIDTH: 89.88%; VERTICAL-ALIGN: middle">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 9.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</div>
</td>
<td style="WIDTH: 0.9%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 89.88%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.22%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 0.9%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="WIDTH: 89.88%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">99</div>
</td>
<td style="WIDTH: 0.9%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="WIDTH: 89.88%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Press Release issued by the Company, dated February 21, 2014.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.22%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 0.9%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="WIDTH: 89.88%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; MARGIN-TOP: 3pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</div>

<div style="TEXT-ALIGN: left; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="MARGIN-TOP: 3pt; MARGIN-BOTTOM: 3pt"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Date: February 21, 2014</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">EMERGENT BIOSOLUTIONS INC.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">By:</div>
</td>
<td style="BORDER-BOTTOM-COLOR: ; WIDTH: 45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt"><u>/s/ROBERT G. KRAMER</u></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Robert G. Kramer</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Executive Vice President and Chief Financial Officer</div>
</td>
</tr>
</table>

<div style="MARGIN-TOP: 3pt; MARGIN-BOTTOM: 3pt"><br>
</div>

<div style="TEXT-ALIGN: center; MARGIN-TOP: 3pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBT INDEX</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 18pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 12.82%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 86.08%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</div>
</td>
</tr>

<tr>
<td style="WIDTH: 12.82%; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="WIDTH: 86.08%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 12.82%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">99</div>
</td>
<td style="WIDTH: 1.09%; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="WIDTH: 86.08%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">Press Release issued by the Company, dated February 21, 2014.</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
</div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8k022114.htm", "secsgml_size_bytes": 21454}]
{"company-data": {"conformed-name": "Emergent BioSolutions Inc.", "cik": "0001367644", "assigned-sic": "2834", "irs-number": "141902018", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33137", "film-number": "14632344"}, "business-address": {"street1": "2273 RESEARCH BLVD, SUITE 400", "city": "ROCKVILLE", "state": "MD", "zip": "20850", "phone": "(301) 795-1800"}, "mail-address": {"street1": "2273 RESEARCH BLVD, SUITE 400", "city": "ROCKVILLE", "state": "MD", "zip": "20850"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
February 21, 2014
Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-33137
14-1902018
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
2273 Research Boulevard, Suite 400, Rockville, Maryland
20850
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(301) 795-1800
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.01
Completion of Acquisition or Disposition of Assets.
On February 21, 2014, Emergent BioSolutions Inc. and its wholly-owned subsidiary, 2396638 Ontario Inc. ("Acquisition Sub"), completed the previously announced acquisition of Cangene Corporation, an Ontario corporation, in accordance with the Arrangement Agreement, dated as of December 11, 2013 (the "Arrangement Agreement"), among Emergent, Acquisition Sub and Cangene. Acquisition Sub paid $222 million in cash, or $3.24 per share (on a fully diluted basis), to acquire all of the outstanding common shares of Cangene. The acquisition was funded, in part, by proceeds from an offering by Emergent of its 2.875% Convertible Senior Notes due 2021 (the "Notes"), which closed on January 29, 2014.
Cangene is a Canadian biopharmaceutical company focused on the development and commercialization of specialty therapeutics, primarily targeting biodefense applications as well as infectious disease, hematology and transplantation.
Additional information and details of the Arrangement Agreement and the Notes, respectively, were previously disclosed in Item 1.01 of Emergent's Form 8-K filed on December 11, 2013 and Item 1.01 of Emergent's Form 8-K filed on January 29, 2014, both of which are incorporated by reference into this Item 2.01.
The foregoing is a summary description of certain terms of the Arrangement Agreement and does not purport to be complete. It is qualified in its entirety by reference to the full text of the Arrangement Agreement, which was attached as Exhibit 2 to Emergent's Form 8-K filed on December 11, 2013.
The representations and warranties of Emergent, Cangene and Acquisition Sub contained in the Arrangement Agreement were made solely for the benefit of the parties to the Arrangement Agreement. In addition, such representations and warranties (1) were made only for purposes of the Arrangement Agreement, (2) may be subject to limits or exceptions agreed upon by the contracting parties, (3) are subject to materiality qualifications contained in the Arrangement Agreement which may differ from what may be viewed as material by investors, (4) were made only as of the date of the Arrangement Agreement or other specific dates and (5) have been included in the Arrangement Agreement for the purpose of allocating risk between the contracting parties rather than establishing matters as facts. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Emergent, Cangene or any of their respective subsidiaries or affiliates. Additionally, the representations, warranties, covenants, conditions and other terms of the Arrangement Agreement were made subject to subsequent waiver or modification. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Arrangement Agreement, which subsequent information may or may not be fully reflected in Emergent's or Cangene's public disclosures.
Item 7.01
Regulation FD Disclosure.
A copy of the Company's press release, dated February 21, 2014, announcing completion of the acquisition is attached to this report on Form 8-K as Exhibit 99 and is incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired
The audited consolidated financial statements of Cangene Corporation, including the consolidated balance sheets as at July 31, 2013 and 2012 and the consolidated statements of income (loss) and comprehensive income (loss), changes in equity and cash flows for the years ended July 31, 2013 and 2012, were included as Exhibit 99.1 to Emergent's Form 8-K filed on January 22, 2014, which is incorporated herein by reference.
The audited consolidated financial statements of Cangene Corporation, including the consolidated balance sheets as at July 31, 2012 and 2011 and the consolidated statements of income (loss) and comprehensive income (loss), changes in equity and cash flows for the years ended July 31, 2012 and 2011, were included as Exhibit 99.2 to Emergent's Form 8-K filed on January 22, 2014, which is incorporated herein by reference.
The unaudited condensed consolidated interim financial statements of Cangene Corporation, including the condensed consolidated interim balance sheets as at October 31, 2013 and July 31, 2013 and the condensed consolidated interim statements of income (loss) and comprehensive income (loss), changes in equity and cash flows for the three months ended October 31, 2013 and 2012, were included as Exhibit 99.3 to Emergent's Form 8-K filed on January 22, 2014, which is incorporated herein by reference.
(b) Pro Forma Financial Information
The unaudited pro forma combined financial statements reflecting the acquisition were included as Exhibit 99.4 to Emergent's Form 8-K filed on January 22, 2014, which is incorporated herein by reference. The unaudited pro forma combined financial statements were prepared prior to the issuance of the Notes. The actual aggregate principal amount of Notes issued in the offering was $250 million, representing $50 million more than the aggregate principal amount of Notes assumed in the pro forma combined financial statements, which results in a $1.4 million increase in pro forma interest expense for the year ended December 31, 2012, a $1.1 million increase in pro forma interest expense for the nine months ended September, 2013, a $0.03 decrease in basic earnings per share for the year ended December 31, 2012, and a $0.02 decrease in basic earnings per share for the nine months ended September 30, 2013.
(d) Exhibits
Number
Exhibit
99
Press Release issued by the Company, dated February 21, 2014.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 21, 2014
EMERGENT BIOSOLUTIONS INC.
By:
/s/ROBERT G. KRAMER
Robert G. Kramer
Executive Vice President and Chief Financial Officer
EXHIBT INDEX
Number
Exhibit
99
Press Release issued by the Company, dated February 21, 2014.